Article Text

Download PDFPDF

4CPS-039 Nosocomial infection by multiresistant pathogens in kidney transplant patients
  1. MJ Morales Lara,
  2. R Tamayo Bermejo,
  3. A Luna Higuera
  1. Hospital Regional Universitario Carlos Haya, Pharmacy, Malaga, Spain


Background and importance Immunosuppression related to organ transplant is a risk factor for multidrug resistant infections.

Aim and objectives To evaluate the prevalence of nosocomial infections (NI) by multidrug resistant (MDR) pathogens, aetiologic agents and treatments given to a cohort of patients undergoing kidney transplantation (KT).

Material and methods A retrospective observational study was carried out in a cohort of patients having undergone a KT during 2016–2017. Variables collected: demographics, clinical (type of KT and aetiologic agent) and therapeutic (induction immunosuppressant treatments and empirical and targeted antimicrobials) data.

Results Sixty-four patients who had undergone a KT (84.4% from a cadaver, 7.8% from a live donor and 7.8% kidney–pancreas) were included (mean age 53.6±15.3 years, 72.9% men).

The most frequent induction immunosuppressant treatments were: basiliximab+mycophenolate–mofetil+steroid+tacrolimus (31.2%) and thymoglobulin+mycophenolate-mofetil+steroid+tacrolimus (65.6%).

Eight of 64 patients developed NI by MDR pathogens during hospitalisation as a result of the KT (prevalence 12.5%), isolating a total of 10 multiresistant causative agents: Escherichia coli (30%), Pseudomonas aeruginosa and Klebsiella pneumoniae (extended spectrum beta lactamase producing, oxa-48 carbapenemase producing (20% each) and carbapenemase producing (10%)).

The sources of NI were: urinary tract (50%), central venous catheter (30%) and abdominal (20%).

Based on patient symptoms, empirical administered antibiotics were: ceftazidime (30%), ciprofloxacin (20%), ceftriaxone (20%), meropenem, levofloxacin (10%) and piperacillin–tazobactam (10%). In all cases, once the aetiologic agent was isolated, targeted treatment was used.

It is worth noting the use of ceftazidime–avibactam in two cases of infection with MDR carbapenemase oxa-48 producing K pneumoniae. None of the patients died due to the NI. Of the patients treated with the immunosuppressant regimen that included basiliximab, 40% developed NI by MDR pathogens in contrast with the group that received the regimen including thymoglobulin (2.5%). This difference was significant (p=0.0875).

Conclusion and relevance In our cohort of patients there was a high prevalence of NI by MDR pathogens, with K pneumoniae the most frequent. Ceftazidime was the most commonly used antibiotic as an empirical treatment, and urinary infections the most prevalent within our population. There seems to be a correlation between developing an infection by MDR pathogens and the induction immunosuppressant treatments that included basiliximab, although prospective studies with a larger sample size are needed to confirm these preliminary results.

References and/or acknowledgements No conflict of interest.

Statistics from

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.